



King's Research Portal

DOI:

[10.1017/S0033291713000883](https://doi.org/10.1017/S0033291713000883)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Stone, J. M., Fisher, H. L., Major, B., Chisholm, B., Woolley, J., Lawrence, J., ... Young, A. H. (2014). Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. *Psychological medicine*, 44(3), 499-506. 10.1017/S0033291713000883

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Cannabis use and first-episode psychosis – relationship to manic and psychotic symptoms, and to age at presentation

Running Title: Cannabis and first-episode psychosis

James M Stone, Clinical Senior Lecturer, BSc. MBBS MRCPsych PhD (1)*

Helen L Fisher, MRC Population Health Scientist, BSc MSc PhD CPsychol AFBPsS (2)

Barnaby Major, Consultant Psychiatrist, BSc MBBS MRCPsych MSc (3)

Brock Chisholm, Principal Clinical Psychologist, DClinPsych (4)

James Woolley, Consultant Psychiatrist, BSc. MBBS MRCP MRCPsych (4)

Jo Lawrence, Clinical Services Leader, MSc (5)

Nikola Rahaman, Consultant Psychiatrist, MBBS MRCPsych (6)

John Joyce, Consultant Psychiatrist, MB BAO BCh MRCPsych (7)

Mark Hinton, Consultant Clinical Psychologist MSc (8)

Sonia Johnson, Professor of Social & Community Psychiatry, BA BM BCh MSc MRCPsych DM (8)

Allan H Young, Professor of Psychiatry MB ChB MPhil PhD FRCPC FRCPsych (1)
on behalf of the MiData Consortium.

(1) Imperial College London, and West London Mental Health Trust, UK

(2) King's College London Institute of Psychiatry, UK

(3) EQUIP, East London NHS Foundation Trust, London, UK

(4) Wandsworth EIS, South West London & St. George's Mental Health NHS Trust, London, UK

(5) Southwark EIS, South London & Maudsley NHS Foundation Trust, London, UK

(6) Kensington, Chelsea & Westminster EIS, Central & North West London NHS Foundation Trust, London, UK

(7) Lewisham EIS, South London and Maudsley NHS Foundation Trust, London, UK

(8) University College London and Camden and Islington NHS Foundation Trust, UK

*corresponding author

email: james.m.stone@imperial.ac.uk

tel: 020 7594 7087

E517

Burlington Danes Building

Hammersmith Hospital

Du Cane Road

London

W12 0NN

Funding Sources: Nil

Background. Cannabis use has been reported to be associated with an earlier onset of symptoms in patients with first-episode psychosis, and a worse outcome in those who continue to take cannabis. In general, studies have concentrated on symptoms of psychosis rather than mania. In this study, using a longitudinal design in a large naturalistic cohort of patients with first-episode psychosis, we investigated the relationship between cannabis use, age of presentation to services, daily functioning, and positive, negative and manic symptoms.

Method. Clinical data on 502 patients with first-episode psychosis was collected using the MiData audit database from 7 London-based Early Intervention in psychosis teams. Individuals were assessed at 2 time points – at entry to the service and after 1 year. On each occasion, Positive and Negative Syndrome Scale, Young Mania Rating Scale, and Global Assessment of Functioning scale disability subscale were rated. At both time-points, the use of cannabis and other drugs of abuse in the 6 months preceding each assessment was recorded.

Results. Level of cannabis use was associated with a younger age at presentation, and manic symptoms and conceptual disorganisation, but not with delusions, hallucinations, negative symptoms or daily functioning. Cannabis users who reduced or stopped their use following contact with services had the greatest improvement in symptoms at 1 year compared to continued users and non-users. Continued users remained more symptomatic than non-users at follow-up.

Conclusions. Effective interventions for reducing cannabis use may yield significant health benefits for patients with first-episode psychosis.

Key words: Cannabis, Schizophrenia, Bipolar Affective Disorder, Mania, Psychosis

Introduction

There is growing evidence that cannabis use may increase the risk of developing schizophrenia (Manrique-Garcia *et al* 2012, Murray *et al* 2007), and that individuals with first-episode psychosis with a history of cannabis use have an earlier onset of psychotic symptoms and younger age at presentation to services (Gonzalez-Pinto *et al* 2011, Large *et al* 2011). Cannabis use has generally been reported to be associated with increased positive symptoms and increase in risk of relapse in patients with schizophrenia, with functional and symptomatic improvements reported to occur on discontinuation (Faber *et al* 2012, Foti *et al* 2010, Grech *et al* 2005, Kuepper *et al* 2011, Zammit *et al* 2008). Cannabis use has also been shown to affect mood (Henquet *et al* 2006), being reported to be associated with depressive symptoms and worse outcome in individuals with bipolar affective disorder (Strakowski *et al* 2007, van Rossum *et al* 2009). To our knowledge, no longitudinal studies have yet examined the relationship of cannabis use to symptoms of mania in patients with first-episode psychosis.

In this study, we examined the temporal relationship of cannabis use to manic and psychotic symptoms and to age at presentation to services in a large UK-based cohort of patients with first-episode psychosis. We hypothesized that cannabis use would be associated with a younger age of presentation to services, and that cannabis use would be associated with a greater level of manic and psychotic symptoms and with poorer daily functioning. We also hypothesized that reducing or stopping cannabis use following the first psychotic episode would be associated with better symptomatic and functional improvement.

Method

Ethical approval for this study was obtained from Wandsworth Research Ethics Committee. The study was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki (1964, 2000). Clinical data were collected using the MiData audit database from 7 London-based Early Intervention in psychosis (EI) teams, covering the London boroughs of Brent,

Camden, City and Hackney, Islington, Kensington and Chelsea, Lewisham, Southwark, Wandsworth, and Westminster (Fisher *et al* 2008, Ghali *et al* 2012). Within each team, clinicians (doctors and care-coordinators) completed training by HLF over a 4 1/2 hour session, including vignettes, practice sessions, and discussion of standardised ratings, and were required to demonstrate high reliability with expert raters (Fisher *et al* 2008). In keeping with standard practice in UK for first-episode psychosis teams, patient inclusion was based on a history of psychotic symptoms that lasted for more than 7 days. Individuals who only experienced psychotic symptoms during acute drug intoxication were not included in the study, but otherwise no prior assumptions were made about the cause or diagnosis of the psychotic illness. Individuals were assessed at 2 time points – at entry to the service and after 1 year in contact with the service. On each occasion, Positive and Negative Syndrome Scale (PANSS) (Kay *et al* 1987), Young Mania Rating Scale (YMRS) (Young *et al* 1978), and Global Assessment of Functioning scale disability subscale (GAF-d) (Endicott *et al* 1976), were rated. At both time-points, the use of cannabis and other drugs of abuse in the 6 months preceding each assessment was recorded using the combined Alcohol and Drug Use scales (Drake *et al* 1996). Each drug was rated by clinicians on an operationalized 4-point scale (No Use, Use, Abuse, Dependence), as previously described (Drake *et al* 1996). On this scale, Use is defined as substance use with no evidence of persistent or recurrent social, occupational, psychological or physical problems related to use, and no evidence of recurrent dangerous use. Abuse is defined as substance use with the presence of any of these features. Dependence is defined as the criteria for Abuse, plus at least 3 of the following 7 items: 1) Much time is spent obtaining or using the substance; 2) Frequent intoxication or withdrawal interferes with other activities; 3) Important activities are given up because of substance use; 4) Continued use despite knowledge of substance-related problems; 5) Marked tolerance; 6) Characteristic withdrawal symptoms; 7) The substance is used to relieve or avoid withdrawal problems. At the second time point, clinical diagnosis and compliance with medication (where known) was also recorded.

Statistical analyses were completed using R version 2.14.1 (Ihaka and Gentleman 1996). We generated a linear model with age at presentation to services as the dependent variable, and level of cannabis use, alcohol use, nicotine use, cocaine use, and stimulant use in the preceding 6 months, gender, ethnicity, social functioning (GAF-d) and symptoms at presentation (PANSS total and YMRS) as independent variables. We then generated four separate linear models with baseline YMRS, PANSS positive (PANSS-P), PANSS negative (PANSS-N) and GAF-d scores as dependent variables and level of cannabis use, alcohol use, nicotine use, cocaine use, and stimulant use in the preceding 6 months, age at presentation, gender and ethnicity as independent variables. In each case, models were simplified using an Akaike information criterion (AIC)-based stepwise method implemented in R (Ihaka and Gentleman 1996). Where cannabis was significantly related to the dependent variable in each ANOVA, we performed post-hoc Pearson's correlations on the level of cannabis use vs. the dependent variable, uncorrected for independent variables.

In the follow-up sample, we compared baseline demographics and clinical measures with the full (baseline only) sample using student's t-test and chi squared test, where appropriate. We used four repeated measures ANOVAs to compare YMRS, PANSS (positive and negative) and GAF-d ratings at baseline and follow-up in 3 groups based on their change in cannabis use over the period of study – 1) patients who reported no cannabis use both at presentation and 1 year follow-up (“abstinent”), 2) patients who reported a reduction or a discontinuation of their use of cannabis (“reduced”), 3) patients who reported a continuation or increase in their use of cannabis (“continued”). For all analyses, histogram and qq plots of residuals were used to confirm normality of data and two-tailed p values were employed to determine statistical significance.

Results

Baseline data on recent cannabis, cocaine, stimulant and alcohol use was available in 502 first-episode patients (320 male, 182 female). Demographic and clinical details are summarized in Table 1. Age at presentation was predicted by a model driven primarily by level of cannabis use in the preceding 6 months (associated with a younger age of presentation; post-hoc, uncorrected $r = 0.18$; $n = 502$; $p = 5 \times 10^{-5}$) but also including level of alcohol use (associated with an older age at presentation) and ethnicity (see Table 2). PANSS-P scores were predicted by a model primarily driven by level of cannabis use (post-hoc, uncorrected $r = 0.16$; $n = 502$; $p = 0.0004$), but also including nicotine use, age and gender (Table 3). YMRS scores were predicted by a model that simplified to include level of cannabis use only ($F(1,500) = 16.67$; $r = 0.18$; $n = 502$; $p = 5.2 \times 10^{-5}$). PANSS-N scores were predicted by a model including alcohol use and gender (Table 4). GAF-d scores were predicted by a model including nicotine use and gender (Table 5).

Post-hoc analyses of individual PANSS-P and YMRS components revealed that level of cannabis use was associated at presentation with increased conceptual disorganisation, excitement and hostility on PANSS-P; and with elevated mood and increased motor activity, sexual interest, irritability, speech – rate and amount, language – thought disorder, and disruptive – aggressive behaviour on YMRS (all p values < 0.005 ; $n = 502$). Of note, cannabis use at presentation was not associated with a significantly greater severity of hallucinations ($p = 0.47$) or delusions ($p = 0.25$).

At one year follow-up, data on cannabis use in 271 first-episode patients was available (54% of baseline sample). Of these, 143 (53%) were non-users of cannabis both at baseline and at follow-up (“abstinent” group), 80 (30%) were cannabis users at baseline but had stopped at follow-up (“reduced” group), and 48 (17%) had either continued or increased their level of cannabis use from baseline to follow-up (“continued” group). Out of the 271 first-episode patients with follow-up data, 221 (81%) had a diagnosis of schizophrenia or schizophreniform psychosis, 27 (10%) had a diagnosis of bipolar affective disorder, 13 (5%) had a diagnosis of depressive psychosis, and in 10 (4%), the diagnosis was not recorded. Of those with a final diagnosis of bipolar affective disorder, 9 (34%), and 7 (26%) were classified as being cannabis abusers and cannabis users, respectively, at

baseline. In terms of medication concordance, 163 (60%) patients were recorded as being compliant with medication, 19 (7%) as non-compliant, and in 89 (33%) patients, this information was not available. The sample with baseline and follow-up data did not differ from the full (baseline-only) sample in terms of age ($t = 0.91$, $p = 0.36$), gender (chisq = 1.16, $p = 0.28$), ethnicity (chisq = 3.415, $p = 0.64$), PANSS-P (mean[SD] = 19.1[7.7]; $t = 1.55$, $p = 0.121$), PANSS-N (mean[SD] = 17.27[8.6], $t = 1.01$, $p = 0.31$), YMRS (mean[SD] = 10.8[9.6], $t = 0.64$, $p = 0.52$), GAF-d (mean[SD] = 48.9, $t = 1.86$, $p = 0.62$), or cannabis use ($t = 1.07$, $p = 0.28$), at presentation.

ANOVA revealed a significant within-subjects effect of time for PANSS-P ($F(1,268) = 163$; $n = 271$; $p < 0.0001$), PANSS-N ($F(1,268) = 63.6$; $n = 271$; $p < 0.0001$), YMRS ($F(1,268) = 87.3$; $n = 271$ $p < 0.0001$) and GAF-d ($F(1,268) = 136$; $n = 271$ $p < 0.0001$) with an improvement in all rating scales between baseline and follow-up (mean[SD] PANSS-P = 12.2[6.4]; PANSS-N = 12.9[7.2]; YMRS = 4.7[6.9]; GAF-d = 64.0[17.6]; $n = 271$). There was a significant interaction between change in cannabis use (“abstinent”, “reduced”, “continued”) and time for PANSS-P ($F(2,268) = 9.93$; $n = 271$; $p < 0.0001$; Figure 1), YMRS ($F(2,268) = 9.39$; $n = 271$ $p = 0.0001$; Figure 2), and GAF-d ($F(2,268) = 6.24$; $n = 271$; $p = 0.002$; Figure 3). There was no significant interaction between change in cannabis use and time for PANSS-N ($F(2,268) = 2.65$, $p = 0.07$). Compared to individuals in the “continued” group for cannabis use, those in the “abstinent” and “reduced” groups had lower PANSS-P ($t = 3.26, 3.77$; $p = 0.001, 0.0003$), YMRS ($t = 2.4, 3.57$; $p = 0.02, 0.0007$) and GAF-d scores ($t = 3.0, 3.66$; $p = 0.004, 0.0004$) at follow-up. Medication concordance was not found to differ with different patterns of cannabis use (90% concordance reported in the “abstinent” group, 90% in the “reduced” group and 86% in the “continued” group, $n = 102, 50, 30$ respectively; Chisq = 0.32, $p = 0.85$).

Discussion

In keeping with previous studies, these data suggest cannabis use is associated with a younger age of presentation to services (Gonzalez-Pinto *et al* 2011, Large *et al* 2011), and that discontinuation or reduction of cannabis use is associated with enhanced symptomatic improvement in patients with

first-episode psychosis (Faber *et al* 2012, Foti *et al* 2010, Grech *et al* 2005, Kuepper *et al* 2011, Zammit *et al* 2008).

In contrast, several recent studies of cannabis use in schizophrenia suggest that change in cannabis use may not affect symptomatology to such a great extent. Three studies failed to demonstrate any change in PANSS positive scores with reduction or discontinuation of cannabis, although in all of these studies, discontinuation was associated with improvement in social functioning (Barrowclough *et al* 2011, Faber *et al* 2012, Gonzalez-Pinto *et al* 2011). Another study found that, although there was no difference in clinical measures between cannabis users and non-users, cannabis users had more frequent hospital admissions (van Dijk *et al* 2012). A further group reported that individuals who continued to take cannabis were more likely to be compliant with medication, but, after correcting for this, cannabis users had higher levels of psychopathology compared to those who discontinued cannabis (Faridi *et al* 2012). Thus, although positive symptoms, as rated by PANSS, are not always associated with cannabis use in patients with schizophrenia and first-episode psychosis, all studies have reported an improvement in functioning with reduction in use. It is also clear that cannabis use may have a complex inter-relationship with medication concordance in some patients, although this did not appear to be an issue in the present study. It is interesting to note, although we found that cannabis did have an effect on PANSS positive scores in the present study, that this effect was primarily driven by aggression and disinhibition, rather than the more usually associated symptoms of delusions and hallucinations. It is possible that the effects of cannabis reduction on illness outcome may be most marked in patients with first-episode psychosis. A recent meta-analysis found that reducing substance intake led to improvements in symptomatology, but that this effect was only present in patients with first-episode psychosis. In patients with more established illness, improvements were not statistically significant (Mullin *et al* 2012).

Although other studies have found that cannabis use is associated with increases in positive affect (self-rated reports of happiness, cheerfulness, relaxation, enthusiasm and satisfaction) in the general

population (Henquet *et al* 2006), and that it can worsen outcome in bipolar disorder (Strakowski *et al* 2007, van Rossum *et al* 2009), our study is the first report, to our knowledge, of cannabis use being associated more closely with manic-type symptoms than with hallucinations and delusions in patients with first-episode psychosis.

Our finding of an association between cannabis use and a younger age of presentation to services is in keeping with current evidence that cannabis use may lead to an earlier onset of psychotic symptoms (Large *et al* 2011). It is possible that individuals with earlier and more severe symptoms may be drawn to take cannabis for other reasons, or that younger individuals may simply be more likely to have taken cannabis in the preceding 6 months due to cannabis use being more prevalent in a younger age group. However, a recent meta-analysis concluded that these possibilities could not fully explain the association between cannabis use and earlier onset of psychosis (Large *et al* 2011). It should be noted that the 6 months prior to contact with services may have coincided with the onset of prodromal symptoms, and we cannot exclude the possibility that cannabis was used in an attempt to self-medicate.

It is interesting to note that, in the present study, the level of PANSS-P scores at baseline were associated with nicotine use (at trend level) and with age, and that lower GAFd scores at baseline were also associated with nicotine use. Previous studies have reported an association between nicotine use and a greater severity of positive symptoms, as well as lower social functioning, in patients with first-episode psychosis and schizophrenia (Krishnadas *et al* 2012, Zhang *et al* 2012). Although the reasons for these associations have not been ascertained, it is possible that nicotine use may worsen symptoms and levels of disability, or may be used as self-medication in an effort to improve some aspects of functioning in the most unwell patients (Krishnadas *et al* 2012, Zhang *et al* 2012). The reason for our finding of an association between age and symptoms in this study is not known, but it is possible to speculate that older individuals were more likely to have been living away from home, with less daily contact from family members, and so their illness may have become more severe before being recognised.

We also found an association between alcohol use and less severe negative symptoms and between male gender and more severe negative symptoms. The finding of an association (albeit weak) between alcohol use and less severe PANSS-negative scores, has not been previously reported, to our knowledge, and may simply reflect the fact that individuals with lower negative symptoms are more capable of getting access to alcohol. The finding that male gender was associated with PANSS-negative scores has been established for many years (Abel *et al* 2010, Andreasen 1982).

There are limitations to this study – most notably that cannabis and other drug use data were dependent on patient recall and disclosure – the alcohol and drug use scales are self-report scales. Furthermore, the data were recorded by a variety of different psychiatric team members who were not blind to treatment status, though all had received the same training. Only 27 patients were diagnosed with bipolar affective disorder at follow-up; therefore, manic-type symptoms, although associated with cannabis use, were unlikely to have been the primary presenting complaint in the majority of cases. Data on cannabis use at follow-up was not available in approximately 46% of the original sample. This was because follow-up assessments were abbreviated in some instances, with recordings of substance use being omitted, due to time pressures on the clinical teams involved in the study. Although the baseline demographics and clinical measures in patients with substance use data at both time points did not differ significantly from those with data from the first time point only, it is possible that the longitudinal analysis may not be fully representative of the total study population.

Despite these limitations, the findings from this study are derived from a relatively large naturalistic cohort with a good coverage of different London teams and regions and so should be generalisable to other inner city services in the UK. This study suggests that efforts to identify effective interventions for reducing cannabis use are likely to yield significant health benefits for patients with first-episode psychosis.

Contributors

SJ and HLF were involved in designing and implementing the MiData database. HLF conducted MiData training with all of the clinicians and completed the merger of the teams' datasets. BM, BC, JW, JL, NR, JJ, MH and SJ contributed to collecting data from their respective Trusts. JMS performed the analysis of the data and wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

Conflict of Interest

AHY has received research grants, honoraria for educational activities and fees for consultancy services from a number of pharmaceutical companies (AstraZeneca, BCI Pharma, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Otsuka Pharmaceutical Co., Pfizer, Sanofi-Aventis, Servier Laboratories, Wyeth). JMS has received a non-restricted academic fellowship from GlaxoSmithKline, and honoraria from Roche, AstraZeneca, Behrenberg Bank, and Pfizer. The authors declare no conflict of interest.

Acknowledgements

Initial pilot work within Camden and Islington EIS was supported by Islington PCT. We are extremely grateful to clinicians and patients from the teams participating as part of the MiData Consortium for their time and enthusiasm: Camden & Islington EIS, EQUIP, STEP, Lewisham EIS, Wandsworth EIS, Kensington, Chelsea & Westminster EIS, and Brent EIS.

Table 1: Demographic and baseline clinical details of EIS psychosis patients.

Demographic or clinical variable	N (%) or M (SD)
Age	23.7 (4.9)
Gender (M/F)	320 (64) /182 (36)
Ethnicity (Caucasian/ Mixed/ Asian/ AC/ Chinese/ Other)	170 (34)/ 43 (9)/ 71 (14)/ 192 (38)/ 24 (5)/ 2 (0)
Education level (no qualifications/ GCSE/ A-Level/ HND or professional qualification/ university but did not complete/ degree/ postgraduate/ other)	107 (21)/ 145 (29)/ 59 (12)/ 22 (4)/ 74 (15)/ 49 (10)/ 9 (2)/ 37 (7)
Employment status (unemployed/ student/ part-time/ full-time/ other)	287 (57)/ 104 (21)/ 37 (7)/ 44 (9)/ 30 (6)
Cannabis use (no use/ use/ abuse/ dependence)	295 (59)/ 95 (19)/ 94 (19)/ 18 (4)
Alcohol use (no use/ use/ abuse/ dependence)	201 (40)/ 252 (50)/ 46 (9)/ 3 (1)
Nicotine use (no use/ use/ abuse/ dependence)	279 (56)/ 164 (33)/ 13 (3)/ 46 (9)
Cocaine use (no use/ use/ abuse/ dependence)	449 (89)/ 39 (8)/ 10 (2)/ 4 (1)
Stimulant use (no use/ use/ abuse/ dependence)	477 (95)/ 19 (4)/ 5 (1)/ 1 (0)
PANSS total	72.0 (24.6)
PANSS positive	18.2 (7.8)
PANSS negative	16.6 (8.3)
YMRS	10.3 (10.1)
GAF-D	51.3 (17.7)

AC – Black African and African-Caribbean, GCSE – General Certificate of Secondary Education. A-level: Advanced-Level General Certificate of Education. HND – Higher National Diploma. PANSS – Positive and Negative Syndrome Scale. YMRS – Young Mania Rating Scale. GAF-d – Global Assessment of Functioning scale – disability subscale, SD, standard deviation.

Table 2: Components of general linear model predicting age at presentation.

	Estimate	Std. Error	t value	p
(Intercept)	25.5	3.33	7.66	9.5×10^{-14}
Cannabis use	-1.18	0.26	-4.55	6.8×10^{-6}
Alcohol use	1.13	0.37	3.06	0.002
Ethnicity (Caucasian)	-1.89	3.35	-0.57	0.57
Ethnicity (Mixed)	-3.28	3.40	-0.96	0.34
Ethnicity (Asian)	-0.11	3.37	-0.032	0.97
Ethnicity (AC)	-2.17	3.34	-0.65	0.52
Ethnicity (Chinese)	-1.10	3.46	-0.32	0.75

$F(7,494) = 5.69$; $p = 2.4 \times 10^{-6}$. AC - Black African and African-Caribbean.

Table 3: Components of general linear model predicting PANSS-positive scores at presentation.

	Estimate	Standard Error	t value	p
(Intercept)	12.6	1.87	6.74	4.5×10^{-11}
Cannabis use	1.12	0.43	2.61	0.0094
Nicotine use	0.73	0.41	1.76	0.079
Age	0.16	0.07	2.16	0.032
Gender (Male)	1.03	0.73	1.41	0.16

$F(3,498) = 5.76$; $p = 0.0002$. PANSS – Positive and Negative Syndrome Scale.

Table 4: Components of general linear model predicting PANSS-negative scores at presentation.

	Estimate	Standard Error	t value	p
(Intercept)	16.62	0.70	23.75	2×10^{-16}
Alcohol use	-1.30	0.56	-2.48	0.013
Gender (Male)	1.55	0.77	2.02	0.044

$F(2,499) = 4.634$; $p = 0.01$. PANSS – Positive and Negative Syndrome Scale.

Table 5: Components of general linear model predicting GAF-d scores at presentation

	Estimate	Standard Error	t value	p
(Intercept)	54.2	1.37	39.69	2 x 10 ⁻¹⁶ 0.046 0.097
Nicotine use	-1.74	0.87	-2.00	
Gender (Male)	-2.74	1.65	-1.66	

F(2,499) = 3.954; p = 0.01. GAF-d – Global Assessment of Functioning scale – disability subscale

Figure 1: Interaction plot of the positive subscale of the Positive and Negative Syndrome Scale (PANSS-P) over time. Figure shows PANSS-P in patients with first-episode psychosis who reported no cannabis use both at presentation and 1 year follow-up (Abstinent), who reported a reduction or a discontinuation of their use of cannabis (Reduced), and who reported a continuation or increase in their use of cannabis between baseline and follow-up (Continued). Error bars show Standard Error of Mean.




Figure 2: Interaction plot of Young Mania Rating Scale (YMRS) over time. Figure shows YMRS in patients with first-episode psychosis who reported no cannabis use both at presentation and 1 year follow-up (Abstinent), who reported a reduction or a discontinuation of their use of cannabis (Reduced), and who reported a continuation or increase in their use of cannabis between baseline and follow-up (Continued). Error bars show Standard Error of Mean.





Figure 3: Interaction plot of the Global Assessment of Functioning scale - disability subscale (GAF-d) over time. Figure shows GAF-d in patients with first-episode psychosis who reported no cannabis use both at presentation and 1 year follow-up (Abstinent), who reported a reduction or a discontinuation of their use of cannabis (Reduced), and who reported a continuation or increase in their use of cannabis between baseline and follow-up (Continued). Error bars show Standard Error of Mean.



References

- Abel KM, Drake R, Goldstein JM** (2010). Sex differences in schizophrenia. *International review of psychiatry (Abingdon, England)* **22**, 417-428
- Andreasen NC** (1982). Negative symptoms in schizophrenia. Definition and reliability. *Archives of General Psychiatry* **39**, 784-788
- Barrowclough C, Emsley R, Eisner E, Beardmore R, Wykes T** (2011). Does Change in Cannabis Use in Established Psychosis Affect Clinical Outcome?. *Schizophrenia bulletin*
- Drake RE, Mueser KT, McHugo GJ** (1996). Clinician rating scales: alcohol use scale (AUS), drug use scale (DUS), and substance abuse treatment scale (SATS). In *Outcomes assessment in clinical practice* (eds. S. L.I., D. B.), pp. 113-116. Williams & Wilkins: Baltimore
- Endicott J, Spitzer RL, Fleiss JL, Cohen J** (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance . *Archives of General Psychiatry* **33**, 766-771
- Faber G, Smid HG, Van Gool AR, Wunderink L, van den Bosch RJ, Wiersma D** (2012). Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial. *The Journal of clinical psychiatry* **73**, 632-638
- Faridi K, Joobar R, Malla A** (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. *Schizophrenia research* **141**, 78-82
- Fisher H, Theodore K, Power P, Chisholm B, Fuller J, Marlowe K, Aitchison KJ, Tanna R, Joyce J, Sacks M, Craig T, Johnson S** (2008). Routine evaluation in first episode psychosis services: feasibility and results from the MiData project . *Social psychiatry and psychiatric epidemiology* **43**, 960-967
- Foti DJ, Kotov R, Guey LT, Bromet EJ** (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization . *The American Journal of Psychiatry* **167**, 987-993
- Ghali S, Fisher HL, Joyce J, Major B, Hobbs L, Soni S, Chisholm B, Rahaman N, Papada P, Lawrence J, Bloy S, Marlowe K, Aitchison KJ, Power P, Johnson S** (2012). Ethnic variations in pathways into early intervention services for psychosis. *The British journal of psychiatry : the journal of mental science*
- Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, Haidar MK, Vieta E, Arango C** (2011). Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. *Schizophrenia bulletin* **37**, 631-639
- Grech A, Van Os J, Jones PB, Lewis SW, Murray RM** (2005). Cannabis use and outcome of recent onset psychosis . *European psychiatry : the journal of the Association of European Psychiatrists* **20**, 349-353
- Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J** (2006). Cannabis use and expression of mania in the general population . *Journal of affective disorders* **95**, 103-110
- Ihaka R, Gentleman R** (1996). R: a language for data analysis and graphics. *J Comput Graph Stat* **5**, 299-314
- Kay SR, Fiszbein A, Opler LA** (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* **13**, 261-76
- Krishnadas R, Jauhar S, Telfer S, Shivashankar S, McCreadie RG** (2012). Nicotine dependence and illness severity in schizophrenia. *The British journal of psychiatry : the journal of mental science* **201**, 306-312
- Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C** (2011). Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study . *BMJ (Clinical research ed.)* **342**, d738
- Large M, Sharma S, Compton MT, Slade T, Nielssen O** (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis . *Archives of General Psychiatry* **68**, 555-561

- Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P** (2012). Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort . *Psychological medicine* **42**, 1321-1328
- Mullin K, Gupta P, Compton MT, Nielssen O, Harris A, Large M** (2012). Does giving up substance use work for patients with psychosis? A systematic meta-analysis. *The Australian and New Zealand Journal of Psychiatry* **46**, 826-839
- Murray RM, Morrison PD, Henquet C, Di Forti M** (2007). Cannabis, the mind and society: the hash realities. *Nat Rev Neurosci* **8**, 885-95
- Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Jr, Arnold LM, Amicone J** (2007). Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania . *Archives of General Psychiatry* **64**, 57-64
- van Dijk D, Koeter MW, Hijman R, Kahn RS, van den Brink W** (2012). Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. *Schizophrenia research* **137**, 50-57
- van Rossum I, Boomsma M, Tenback D, Reed C, van Os J, EMBLEM Advisory Board** (2009). Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis . *The Journal of nervous and mental disease* **197**, 35-40
- Young RC, Biggs JT, Ziegler VE, Meyer DA** (1978). A rating scale for mania: reliability, validity and sensitivity . *The British journal of psychiatry : the journal of mental science* **133**, 429-435
- Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G** (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. *The British journal of psychiatry : the journal of mental science* **193**, 357-363
- Zhang XY, Chen DC, Xiu MH, Haile CN, He SC, Luo X, Zuo L, Rosenheck R, Kosten TA, Kosten TR** (2012). Cigarette smoking, psychopathology and cognitive function in first-episode drug-naïve patients with schizophrenia: a case-control study. *Psychological medicine*, 1-10